TriLink Secures Contract for the Synthesis of Ebola Vaccine
Complete the form below to unlock access to ALL audio articles.
TriLink BioTechnologies (TriLink) announced that it secured a contract with Battelle for the manufacture of mRNA to support vaccine development against filoviruses. The contract is in support of a project conducted by Medical Countermeasure Systems (MCS) – Joint Vaccine Acquisition Program (JVAP). MCS-JVAP works in conjunction with the Department of Defense to advance development, testing, FDA licensing, production, and storage of biological defense vaccines.
The overall goal of the MCS-JVAP project is to create a trivalent vaccine effective against aerosolized exposure to Ebola Sudan, Ebola Zaire, and Marburg viruses. These viruses are highly lethal and may be used as biological warfare agents. Currently there are limited measures to fight against filovirus infections. TriLink’s role is to synthesize the mRNA needed for preclinical studies and scale up the process in preparation for the synthesis of clinical grade material.
"We are very excited to have been awarded this contract with Battelle for the MCS-JVAP project. TriLink is well known for our expertise in modified nucleic acid chemistry and mRNA manufacturing. This, coupled with our experience in the production of alphavirus replicons aligns well with the fundamental needs of this research, " said TriLink President and CEO, Dr. Richard Hogrefe. “Because we are a pharmaceutical grade GMP manufacturer we will be able to see this project into the clinic.”
The project is sponsored by the Defense Technical Information Center. ATTN: DTIC-AI, B723 John J. Kingman Rd., Ste 0944, Fort Belvoir, VA 22060-6218.
